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A B S T R A C T
The incidence of squamous cell carcinoma of the anal canal (SCAC) is increasing in both sexes but the standard
treatment remains that of 20 years ago. However, interesting data have recently emerged on the use of anti-
epidermal growth factor receptor (EGFR) agents and immunotherapy in advanced disease. Thus, new avenues of
research are opening up that will hopefully lead to more effective therapeutic strategies. We provide an overview
of the latest studies published on this tumor and discuss the possible future therapeutic options for combination
therapy, anti-EGFR treatment and radiotherapy.
1. Introduction
Squamous cell carcinoma of the anal canal (SCAC) represents 2.5%
of all gastrointestinal cancers. However, the incidence of this tumor is
gradually increasing in both sexes due to infection from human pa-
pilloma virus (HPV) (Altekruse et al., 1975). Five-year survival is 80%
for localized disease (Johnson et al., 2004). In the past, abdominoper-
ineal resection and permanent colostomy was the standard therapy for
non-metastatic disease and 5-year survival was 50–60% (Clark et al.,
2004). In 1974 Nigro et al. (1974) reported a complete response (CR) in
3 patients treated with a combination of radiation therapy and che-
motherapy (mitomycin C and 5-fluorouracil [5-FU]). However, no
phase III randomized trials comparing abdominoperineal resection with
radiochemotherapy have been conducted to date. Furthermore, there
are virtually no data in the literature on the treatment of metastatic
SCAC, the current standard of care for which is cisplatin and 5-FU
(Faivre et al., 1999; Jaiyesimi and Cisplatin, 1993; Tanum, 1993;
Khater et al., 1986; Ajani et al., 1989). The overall response rate is 60%,
with a median survival of 12 months. As with localized disease, treat-
ment for advanced disease has not changed in the last 20 years. How-
ever, several interesting studies have been published in this area over
the past 12 months. The present review evaluates the latest data pub-
lished on SCAC and discusses the future therapeutic options for com-
bination therapy, anti-EGFR treatment and radiotherapy.
2. Role of anti-EGFR therapy in the treatment of SCAC
Epidermal growth factor receptor (EGFR) is overexpressed in about
90% of SCAC, whereas KRAS and NRAS mutations are rare (Capelli
et al., 2016; Casadei Gardini et al., 2014; Zampino et al., 2009; Cacheux
et al., 2016). PIK3CA is mutated in 20% of patients (Capelli et al.,
2016). These observations provide a theoretical rationale for in-
tegrating anti-EGFR agents into standard treatment for SCAC. Fig. 1
summarizes the chemoradiotherapy schedules of the most important
studies carried out to date and Table 1 reports the main results ob-
tained. In 2013, Olivatto et al. were the first to evaluate the use of
cetuximab (Olivatto et al., 2013) in a phase I study in which cetuximab
was administered with cisplatin and 5-FU in concomitance with
radiotherapy. The study was closed due to challenging safety results. All
23 patients enrolled experienced grade 3/4 toxicity (100%): radiation
dermatitis in 52.1% of cases, diarrhea in 43.4%, thrombosis and em-
bolism in 26% and infection in 21%. With regard to efficacy, en-
couraging results were reported, with 95% of patients achieving a pa-
thological CR and a 3-year locoregional control rate of 64.2%. In the
same year, Deutsch et al. published the results of the UNICANCER
ACCORD 16 phase II trial (Deutsch et al., 2013) in which the same
regimen was used to treat 16 patients. However, the study was pre-
maturely closed because of severe toxicity in 88% of the population.
With regard to efficacy, 55% of patients showed a CR and 45% a partial
response (PR). Median objective response duration was 14.7 months.
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38% of patients relapsed after a median follow-up of 22 months. One-
year colostomy-free survival was 67%, one year progression-free sur-
vival (PFS) was 62% and one-year overall survival (OS) was 92%.
In 2015, Leon et al. (2015) published their findings of a phase I
study evaluating cetuximab, mitomycin C and 5-FU in concomitance
with radiotherapy. Thirteen patients were enrolled. The most common
grade 3 and 4 side-effects were radiation dermatitis in 63% of patients,
hematologic toxicity in 54% and diarrhea in 36%. No treatment-related
deaths were recorded. Estimated 2-year relapse-free survival (RFS) and
OS was 73% and 88%, respectively.
The results from the phase II E3205 study (Garg et al., 2017) were
published in March 2017. Patients received cetuximab, cisplatin and 5-
FU at the same dosages as those of the aforementioned studies. Of the
61 patients enrolled, 19 (32%) had grade 4 toxicity and 3 (5%) died
Fig. 1. Treatment scheme of the most important studies on SCAC. 5-FU, 5-fluorouracil; IV, intravenous; RT, radiation therapy; MMC, mitomycin C.
Table 1
Results from the most relevant studies with anti-EGFR antibodies on SCAC.
Grade 3/4
adverse event
%
Treatment-
related death%
Median objective
response
(months)
One-year
colostomy-free
survival%
Complete
response%
Partial
response%
Locoregional control
rate (2-year) (3-year) %
PFS (1-
year) (3-
year) %
OS (1-year)
(2-year) (3-
year) %
Olivatto
et al.
86 NA NA NA 95 NA (NA) (NA) (NA)
(64.2) (NA) (NA)
(NA)
Deutsch
et al.
88 0 14.7 67 55 45 (NA) (62) (92)
(NA) (NA) (NA)
(NA)
Leon et al. 81.8 0 NA NA 91 NA (73) (NA) (NA)
(NA) (NA) (88)
(NA)
E3205 study 32 5 NA NA 59 NA (NA) (NA) (NA)
(77) (68) (NA)
(83)
AMC045
study
26 4.4 NA NA 62 5 (NA) (NA) (NA)
(58) (72) (NA)
(79)
SCAC, squamous cell carcinoma of the anal canal; PFS, progression-free survival; OS, overall survival; NA, not available.
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from treatment-related causes. The objective response rate was 65%.
15% of patients had locoregional recurrence after 3 years. The findings
of the AMC045 trial (Sparano et al., 2017) were published around the
same time. Forty-five HIV-positive patients were enrolled onto the
study: grade 4 toxicity occurred in 12 (26%) cases and there were 2
(4%) treatment-associated deaths. The 3-year locoregional failure rate
was 42%, 3-year PFS was 72% and 3-year OS was 79%. The locor-
egional failure rate was nonetheless low when compared with historical
data. There were, however, several differences between the two study
populations. In the AMC045 study the mean age was lower (47 years),
more than 70% of patients had initial-stage disease (cT1 or T2) and the
majority received modulated intensity (IMRT) radiotherapy, resulting
in lower toxicity. However, the toxicity observed, especially in terms of
the percentage of toxic deaths, was unacceptable in this patient setting.
There are very few data available on advanced SCAC. In 2009 Lukan
et al. (Lukan et al., 2009) published the results of a study on 7 patients
treated with cetuximab. The 2 patients with KRAS-mutated tumors
progressed, whereas among the 5 patients with KRAS wild type disease,
3 had a partial remission, one had a minor remission and one pro-
gressed. In 2016, Rogers et al. (2016) published a retrospective study
on 17 SCAC patients treated with cetuximab or panitumumab, 35% of
whom achieved a CR and 24% stable disease (SD). Median PFS and OS
were 7.3 and 24.7 months, respectively. Recently, Kim et al. (2017)
published results from a retrospective study on 13 patients treated with
anti-EGFR therapy alone or in combination with chemotherapy. Data
confirmed good efficacy (the disease control rate was 46.2%) with ac-
ceptable PFS and OS (4.4 months and 11.4 months, respectively). Fi-
nally, several case reports have also been published suggesting the
potential clinical activity of cetuximab in this setting (Barmettler et al.,
2012; Rogers et al., 2015). The promising findings obtained could form
the basis for the use of anti-EGFR agents in future phase II or III studies
on advanced SCAC.
3. Role of immunotherapy in the treatment of metastatic SCAC
Immunosuppression is a risk factor for SCAC development (Nelson,
2017) and predisposes the anal epithelium to human papillomavirus
(HPV) infection and its persistence. Affecting around 95% of patients
with metastatic SCAC, the virus integrates into the host cell DNA and
promotes oncogenesis (Capelli et al., 2016). It has been demonstrated
that HPV increases the risk of cancer of the head and neck, uterine
cervix, penis and vulva (Faivre et al., 1999; Jaiyesimi and Cisplatin,
1993). HPV-16 subtypes are the most common in SCAC patients. HPV-
associated oncogenesis is caused by viral DNA oncoproteins. These non-
self proteins, which are present within tumor cells, could play a po-
tentially important role in the rationale of emerging targeted im-
munotherapies for SCAC. Table 2 reports the main results obtained with
immunotherapy to date.
A retrospective study (Gujja et al., 2015) of 41 patients with SCAC
reported a prevalence of programmed death-ligand 1 (PD-L1) expres-
sion of 56%. No significant differences in survival were noted between
patients with varying levels of PD-L1 expression. The KEYNOTE-028
study conducted by Ott et al. (2017) enrolled 43 patients, 32 of whom
were PDL-1 positive. All patients had undergone treatment with other
lines of chemotherapy before entering the study. Twenty-five patients
underwent treatment with pembrolizumab at the dose of 10mg/kg
once every 2 weeks. 65% experienced adverse events, only 16% of
which were grade 3 and 4. The overall response rate was 17% and
another 42% of patients obtained SD. Median PFS was 3.0 months and
median OS was 9.3 months.
In the recent study by Morris et al. (2017) on the use of nivolumab
in SCAC, the majority of the 37 patients enrolled had previously re-
ceived at least two lines of treatment. 24% of patients responded (7 PR
and 2 CR), with a durable response (median duration 5.8 months). The
median reduction in the number of target lesions from baseline for
responders was 70%, an interesting result considering that this was
third-line treatment. Median PFS was 4.1 months and median OS was
11.5 months, with an estimated one-year overall survival of 48%.
SCAC occurs frequently in patients with human immunodeficiency
virus (HIV) (Capelli et al., 2016). Yanik et al. reported that HIV status
did not correlate with the degree or composition of PD-L1 expression in
the tumor (Yanik et al., 2017), suggesting that anti-PD-1/PD-L1 drugs
could be used, regardless of HIV status. Of the 2 HIV-positive patients
enrolled in Morris’ study on nivolumab, neither experienced grade 3 or
4 adverse events and one showed a PR.
4. Combination of anti-EGFR therapy, immunotherapy and/or
radiotherapy
Therapeutic monoclonal antibodies consist of two fragments: an-
tigen-binding fragments (Fab) and a crystallizable fragment (Fc). Fab
fragments bind tumor antigens, while the Fc fragment mediates the
binding and activation of immune cells. Cetuximab influences the im-
mune response via 2 interactions: 1) Fab binds its target and the first
component of complement (C1q) to Fc fragments, leading to the acti-
vation of the classic complement pathway (Gancz and Fishelson, 2009);
and 2) tumor cells and bound antibodies are recognized by natural
killer (NK) cells, resulting in the activation of NK cells and cytotoxic T-
lymphocytes and subsequently in damage to the tumor cell membrane
(Bakema and van Egmond, 2014). Cetuximab and panitumumab acti-
vate the immune system differently. Cetuximab is a chimeric IgG1 an-
tibody whereas panitumumab is a fully human IgG2 antibody with
significantly lower immunogenicity (Mellor et al., 2013). Thus, the
combination of cetuximab and monoclonal antibodies targeting CTLA4
and PD-1 antigens is a promising strategy.
The combination of radiotherapy and immunotherapy has also
proven feasible. Radiation therapy in SCAC has an immunomodulatory
impact (Martin et al., 2017) confirmed by the delayed response ob-
served after the end of treatment. The activation of an immune response
with progressive tumor eradication over several weeks could be a
plausible explanation for this well known clinical phenomenon
(Glynne-Jones et al., 2017).
Over the last few years, numerous preclinical studies have demon-
strated that the combination of local irradiation and immunotherapy
synergistically induces antitumor immunity (Reynders et al., 2015).
Furthermore, an abscopal effect has already been described, i.e. a re-
duction or disappearance of metastatic deposits following the treatment
of the primary tumor mass with radiotherapy. For this reason, we
Table 2
Results from the most important studies on immunotherapy in SCAC.
G3/G4
adverse
event%
Treatment-
related death%
Median time to
response
(months)
Complete
response%
Partial
response%
Stable
disease%
Median PFS
(months)
Median OS
(months)
Six-
month OS
%
One-
year OS
%
Ott et al. (pembrolizumab)
(Rogers et al., 2015)
16 0 3.6 0 17 42 3.0 9.3 64.5 47.6
Morris et al. (nivolumab)
(Nelson, 2017).
13.5 0 5.8 5.4 13.5 47 4.1 11.5 NA 48
SCAC, squamous cell carcinoma of the anal canal; PFS, progression-free survival; OS, overall survival; NA, not available.
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believe that the combination of irradiation and immunothrapy could
determinate a synergistic effect. Currently, there is only one study on-
going to assess the efficacy of nivolumab after combined modality
therapy in patients with high-risk stage II-IIIB anal cancer (Anon.,
2018).
In this regard, head and neck cancers have been widely investigated
and several authors have reported PD-1and tumor infiltrating lym-
phocyte (TIL) expression in HPV-positive patients which correlates with
a better response to chemoradiotherapy and a superior outcome
(Badoual et al., 2013; Partlová et al., 2015). Several studies have sug-
gested that PD-1, PD-L1 and CD8 expression and TIL concentration may
influence the efficacy of immunotherapy. Furthermore, a recent paper
by Balermpas et al. reported a correlation between HPV-16 positivity,
PD-1 expression and TIL concentration (Balermpas et al., 2017). In fact,
results highlighted a response to immunotherapy in HPV-16-positive
patients whose tumors showed high PD-1 and TIL levels. These findings
pave the way towards a more rationale development of anti-EGFR plus
immunotherapy combinations in SCAC and may justify the use of HPV-
16 positivity and PD-1, PD-L1 and TIL expression as stratification fac-
tors in future studies.
5. Conclusions
Although there are high hopes for the combination of radiotherapy
and immunotherapy in the treatment of SCAC, several issues remain to
be clarified. In addition to identifying the most effective im-
munotherapeutic drugs, the best combination of radiotherapy and im-
munotherapy must also be determined. In fact, although radiation leads
to the recruitment of immune cells in the tumor, it also induces apop-
tosis in mature NK cells. Further studies are needed to address these
important issues.
Treatment with EGFR inhibitors is also considered a promising ap-
proach. Although chemoradiotherapy has shown important treatment-
related toxicity, the 2 most recent studies reported good efficacy and
tolerability to treatment with lower doses of radiotherapy. With regard
to advanced disease, interesting results have been obtained with im-
munotherapy. The association of cetuximab and immunotherapy is also
an interesting possibility as the EGFR inhibitor is known to exert an
influence on the immune system and may thus increase the efficacy of
immunotherapeutic drugs. There is currently no clinical trial ongoing to
test this association.
In conclusion, whilst it may be too early to boast of a new era in the
treatment of anal carcinoma, a change for the better has begun.
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